You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Innovative Mitigation of Radiation Effects in Advanced Technology Nodes
SBC: MICROELECTRONICS RESEARCH DEVELOPMENT CORPORATION Topic: DTRA16A003Micro-RDC has developed portable radiation effects test structures that scale to new process nodes.These structures will enable the investigation of the effects of radiation on the new technology from the material processing level as well as the circuit level.Fabricating the chosen structures and the refinement of software to extract the model parameters will be completed in this effort.A suite of ...
STTR Phase II 2018 Department of DefenseDefense Threat Reduction Agency -
An Engineered Nanoimmunotherapy for Melanoma
SBC: IMMUNOBLUE, LLC Topic: NCIPROJECT SUMMARY Melanoma is one of the most prevalent cancers and is estimated to account for overdeaths inin the United States aloneAlthough highly curable when detected earlytheyear survival rates decline precipitously for patients with regionaland metastaticmelanoma indicating a lack of efficacy of conventional therapiesand a strong need for novel therapies for this patient populationIn respons ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Building an evidentiary case for circulating GHBP as a biomarker for drug-associated stunting of growth
SBC: REVERAGEN BIOPHARMA, INC. Topic: NICHDThere is increasing interest in the use of biomarkers in clinical drug developmentwith much of thest Century Cures Act focused on encouraging this approachIdeallybiomarkers could provide and acute and objective read out of drug mechanism of actionpharmacodynamic biomarkersor prediction of later clinical benefit or harmsurrogate outcome measureHoweververy few biomarkers have been validated for rout ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Glycoengineering a bioconjugate vaccine against Klebsiella pneumoniae
SBC: VaxNewMO Topic: NIAIDPROJECT SUMMARY Klebsiella pneumoniae is an increasingly prevalent drug resistant nosocomial pathogenCommonlyKpneumoniae isolates are carbapenem resistantwhich are referred to as carbapenem resistant EnterobacteriaceaeCREand present significantly less therapeutic intervention optionsFurthermorecommunity acquired infections associated with hypervirulent isolates of Kpneumoniae have emerged that are ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Noninvasive placement and activation of deep-brain stimulating magnetic particles for reduction of drug-seeking behaviors
SBC: WEINBERG MEDICAL PHYSICS, INC. Topic: NIDAAbstract Deep brain stimulationDBSwith implantable electrodes has been used for reduction of ethanol abuse and drug seeking behaviors in EuropeThe use of such deep brain stimulation procedures has been problematic because of concerns about invasiveness of the procedureApplicant has developed a new noninvasive method of transporting magnetic particles directly to target sites within the brainWe pro ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Expansion of Immuno-CometChip Platform
SBC: AMELIA TECHNOLOGIES LLC Topic: NIEHSProject SummaryThe objective of this supplementation request is to further our recent advances in the development of thewell Immuno CometChip assay results and build a prototypewell preformer giving the assay more utility and increasing commercial viability
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Nucleobase aminosugars with reduced ototoxicity
SBC: NUBAD LLC Topic: YPROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of a Clinical Screening Platform for Type 1 Diabetes
SBC: Op-T-Mune, Inc Topic: NIDDKAbstractA major shortfall in clinical care for diabetes is a rapid and accurate screen for progression to diseaseCurrent criteria involve HLA haplotypeand the presence of auto antibodiesAAGenome wide associated studiesGWASrevealed only immune associated genes including HLA as T D predictorsThe ability to differentiate from other diseases was very limitedPre typediabetesp T Dis now being identified ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
A nanotechnology approach to higher brain penetrance and sustained brain delivery of intranasal oxytocin
SBC: DD Therapeutics, LLC Topic: NIDAPsychostimulant abuse is a significant public health problemwithmillion Americans reporting cocaine use andmillion reporting methamphetamine useCurrentlythere are no FDA approved pharmacotherapies to treat stimulant dependencePrevious cocaine medications development efforts have focused on small molecule drugs as they can readily enter the brainThe lack of brain penetrance by large molecules was s ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
SBC: LEUKOGENE THERAPEUTICS INC Topic: 102Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health